# Acneiform drug eruptions—update on pathophysiology and culprit drugs

## TL;DR

This paper reviews how certain medications can cause acne-like skin reactions and highlights the importance of managing these side effects without stopping essential treatments.

## Contribution

The paper provides an updated overview of the pathophysiology and drugs associated with acneiform adverse drug reactions.

## Key findings

- Acneiform ADRs often involve non-seborrheic body sites and can occur outside typical acne age ranges.
- Epidermal growth factor receptor inhibitors and janus kinase inhibitors are strongly linked to acneiform ADRs.
- Symptomatic treatment is often preferred over discontinuing essential medications.

## Abstract

Acneiform adverse drug reactions (ADRs) appear within weeks to months after the initiation of a new medication. As opposed to acne vulgaris, they typically present monomorphic inflammatory lesions, may involve atypical, non-seborrheic body sites and may arise outside the usual age range of any acne subtype. A wide range of drugs can trigger the eruption of acneiform ADRs with targeted therapies used in oncology (e.g., epidermal growth factor receptor inhibitors) carrying the highest risk. More recently, an increasing incidence of acneiform ADRs has been observed with the advent of januskinase inhibitors now being used in a wide range of inflammatory conditions. Many times, symptomatic treatment rather than discontinuation of the causative drug is feasible, particularly when the medication is essential for managing a serious underlying condition. Close cooperation between dermatologists and prescribing specialists is essential to manage cutaneous side effects enabling maintenance of the best available therapeutic regimen.